A key group within the New York City’s Democratic Socialists of America chapter narrowly voted against endorsing City Councilman Chi Osse’s Dem primary challenge against House Minority Leader Hakeem ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Mayor-elect Zohran Mamdani argued that an endorsement of a left-leaning ally, Chi Ossé, would hurt his efforts to secure mainstream Democratic support for his proposals. By Benjamin Oreskes Of all the ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Over the last several months, Diana Moreno has spent much of her spare time knocking on doors, asking New Yorkers to vote for her fellow organizer and longtime friend, Zohran Mamdani. And though the ...

The election of Zohran Mamdani as mayor of New York represents a seismic victory for the Democratic Socialists of America. Yet even as the DSA seems poised for a political breakthrough, it shows signs ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

The New York City chapter of the Democratic Socialists of America is on the verge of electoral success, with polls saying DSA-backed Assembly Member Zohran Mamdani is leading the race to be the next ...

As foreign policy negotiators work to broker a lasting peace in the Middle East, the Democratic Socialists of America have issued a statement rejecting the current ceasefire. In an Oct. 13, statement ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...